Skip to main content
. 2017 Mar 3;7:61. doi: 10.1038/s41598-017-00138-3

Table 1.

Clinical characteristics of study patients.

GHS (n = 350) GMS (n = 698) FMS (n = 431)
Males (%) 238 (68.0) 344 (49.3) 224 (52.0)
Age at recruitment (yrs) 64.5 ± 8.2 61.3 ± 9.9 63.2 ± 11.6
Smokers (%) 58 (16.6) 102 (14.6) 71 (16.5)
Diabetes duration (yrs) 13.9 ± 9.2 10.3 ± 8.8 13.1 ± 10.1
BMI (kg/m2) 30.1 ± 4.8 31.0 ± 5.7 30.0 ± 6.1
HbA1C (%), (mmol/mol) 8.6 ± 1.9, (70 ± 20.8) 8.7 ± 2.0, (72 ± 21.9) 9.1 ± 2.2, (76 ± 24.0)
Insulin (w/wo) oral agents (%) 191 (54.6) 271 (38.8) 157 (36.4)
Anti-hypertension therapy (%) 296 (84.6) 323 (46.3) 291 (67.5)
Anti-dyslipidemia therapy (%) 227 (64.8) 195 (27.9) 162 (37.6)
Resistin (ng/ml) 10.7 ± 6.7 10.1 ± 8.1 8.5 ± 6.2
Follow-up (yrs), (py) 5.4 ± 2.5; (1,890) 10.8 ± 3.5; (7,504) 7.1 ± 2.5; (3,060)
Events (n) 78 206 119
IR (n. events per 100 py) 4.1 2.7 3.9

Continuous variables were reported as mean ± SD whereas categorical variables as total frequency and percentages. GHS: Gargano Heart Study; GMS: Gargano Mortality Study; FMS: Foggia Mortality Study; BMI: body mass index; HbA1c: glycated haemoglobin; IR: incidence rate of all-cause death events; py: person-years.